The National Institutes of Health Chronic Prostatitis Symptom Index: Development and Validation of a New Outcome Measure

Litwin, Mark S.; McNaughton-Collins, Mary; Fowler, Floyd J.; Nickel, J. Curtis; Calhoun, Elizabeth A.; Pontari, Michel A.; Alexander, Richard B.; Farrar, John T.; O’Leary, Michael P.

doi:10.1016/s0022-5347(05)68562-x

Cited by 841 publications

(599 citation statements)

References 19 publications

Supporting

Mentioning

560

Contrasting

Unclassified

Order By: Relevance

“…Patients were evaluated, including a detailed medical history, physical examination, serum prostate-specific antigen, transrectal ultrasonography, uroflowmetry, postvoiding residual (PVR) urine volume measurement using bladder scans (BVI-3000, Diagnostic Ultrasound Co., Redmond, WA, USA) and symptom score evaluation using the National Institutes of Health (NIH)-Chronic Prostatitis Symptom Index (CPSI) 11 and the International Prostate Symptom Score (I-PSS). 12 First voided urine, midstream urine, expressed prostatic secretions and urine after massage as well as ejaculate were microscopically examined and cultured.…”

Section: Methodsmentioning

confidence: 99%

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Paick

2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this study was to evaluate whether extracorporeal magnetic innervation (ExMI) combined with a-blocker therapy is more effective than a-blocker monotherapy for patients with non-inflammatory chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS), category IIIB. Patients were randomized to either terazosin monotherapy (group 1, n ¼ 21) or terazosin combined with ExMI therapy (group 2, n ¼ 19). Patients in group 2 had 12 treatment sessions of ExMI twice a week during 6 weeks. None of the patients experienced any side effects from treatment. The changes in each domain of the National Institutes of Health (NIH)-Chronic Prostatitis Symptom Index (CPSI) measured on week 6 were not significantly different between the groups. However, the difference (median, 25-75th percentiles) between the two groups in total NIH-CPSI scores was À4 (À11.5, À2) for group 1 and À12 (À17.3, À2.3) for group 2, respectively (P ¼ 0.047). At 6 weeks, 47.6% (10 of 21) of group 1 had a 425% decrease in total NIH-CPSI compared with 78.9% (15 of 19) of group 2 (P ¼ 0.041). Also, more patients in group 2 (78.9%) were rated as responders with a 6-point decrease in NIH-CPSI compared with group 1 (47.6%) (P ¼ 0.041). The early results suggest that ExMI combined with a-blocker therapy has better effect than a-blocker monotherapy for the treatment of CP/CPPS.

show abstract

Section: Methodsmentioning

confidence: 99%

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Paick

2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…For men-the NIH Chronic Prostatitis Symptom Index (CPSI) a nine-question validated questionnaire that allows quantification of the pain, voiding symptoms and quality of life. 9 …”

Section: A Phenotypic Classification Of Ucppsmentioning

confidence: 99%

Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes

Shoskes

Nickel

Rackley

et al. 2008

Prostate Cancer Prostatic Dis

176

105

View full text Add to dashboard Cite

The urologic chronic pain conditions such as chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis are syndromes whose evaluation and management are controversial. Part of the difficulty in diagnosis and therapy is the heterogeneity of etiologies and symptoms. We propose a six-domain phenotype, which can classify these patients clinically and can direct the selection of therapy in the most evidence based multimodal manner. The domains are urinary, psychosocial, organ specific, infection, neurologic and tenderness of skeletal muscles. This system is flexible and responsive to new biomarkers and therapies as their utility and efficacy are proven.

show abstract

“…The National Institute of Health (NIH) has formulated a Chronic Prostatitis Pelvic Pain Research Network (CPPRN) and validated a symptom questionnaire. This questionnaire is now standard for comparison of studies related to CP/CPPS [14]. Cheah et al [15] in a randomized placebo controlled study have shown that terazosin (titrated from 1-5 mg over a period of 14 weeks) signifi cantly decreased the mean chronic prostatitis symptom index (CPSI) score from 25.1 to 10.8.…”

Section: A Brief Review Of Clinical Trialsmentioning

confidence: 99%

Role of alpha blocker therapy in chronic prostatitis/chronic pelvic pain syndrome: limited options with promising results

Singh

Sinha

2008

Indian J Surg

View full text Add to dashboard Cite

Chronic prostatitis / chronic pelvic pain syndrome (NIH-type II and type III prostatitis) are common cause of chronic pelvic pain. The exact etiology of these entities are unknown. They are associated with varying degree of voiding and sexual dysfunction. Consensus regarding treatment of these pain syndromes is lacking. Review of literature suggest a therapeutic role of alpha adrenergic receptor blockers in the management of NIH-type II and type III prostatitis. A trial of alpha-blocker is reasonably inexpensive and appropriate for most patients suffering from NIH-type III prostatitis and NIH-type II prostatitis. A general consensus is that if a patient agrees to a trial of alphablocker therapy which subsequently shows a good response then it should be continued for at least 6 months for a proper therapeutic effect. This review analyses the role of alphablockers in this disease/syndrome; discusses the possible mechanism of action through which these drugs provide relief and also highlights some of the important trials which have paved way for this particular treatment option in this intriguing disease /syndrome. Keywords Prostate . . Pain . . Adrenergic alpha antagonists . . Chronic prostatitis with chronic pelvic pain syndrome.

show abstract

The National Institutes of Health Chronic Prostatitis Symptom Index: Development and Validation of a New Outcome Measure

Cited by 841 publications

References 19 publications

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes

Role of alpha blocker therapy in chronic prostatitis/chronic pelvic pain syndrome: limited options with promising results

Contact Info

Product

Resources

About